MedTrace Logo

A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients

NCT00391196 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 975

Last updated 2012-11-07

No results posted yet for this study

Summary

The purpose of this study is to determine if CP-945,598 is effective in the treatment of obesity in type 2 diabetic patients.

Conditions

Interventions

DRUG

Placebo

Subjects receive placebo plus non-pharmacological weight loss program.

DRUG

CP-945,598

Subjects receive CP-945,598 plus non-pharmacological weight loss program.

DRUG

CP-945,598 Treatment B

Subjects receive CP-945,598 plus non-pharmacological weight loss program.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-12-31
Completion
2009-01-31

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Canada
  • Czechia
  • Germany
  • Mexico
  • Slovakia
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00391196 on ClinicalTrials.gov